NCT02635984View on ClinicalTrials.gov

Study of FOND Versus FOND+O for the Prevention of CINV in Hematology Patients Receiving Highly Emetogenic Chemotherapy Regimens

PHASE3CompletedINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2017

Conditions
Complications of Bone Marrow TransplantHematologic Neoplasms
Interventions
DRUG

Olanzapine

Olanzapine 10mg by mouth once daily on all chemotherapy days and for three days post-chemotherapy

DRUG

Placebo

Placebo tablet taken by mouth once daily on chemotherapy days and for 3 days post chemotherapy

Trial Locations (1)

30912

Augusta University Medical Center, Augusta

All Listed Sponsors
collaborator

University of Georgia

OTHER

lead

Augusta University

OTHER

NCT02635984 - Study of FOND Versus FOND+O for the Prevention of CINV in Hematology Patients Receiving Highly Emetogenic Chemotherapy Regimens | Biotech Hunter | Biotech Hunter